Briefly, to demonstrate the efficacy and safe of the novel structure of dual-receptor CAR in vivo, mice were inoculated with various cancer cells, including AsPC-1 (MSLN+ CEA+), HT29 (MSLN− CEA+), U87 (MSLN+ CEA−), or PANC-1 (MSLN− CEA−), followed by intravenous injection of modified T cells or mock T cells 7 days later. The gene discussed is CEACAM5; the disease is cancer.